National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.

DPP4I were the most commonly utilised agents in metformin-based combination therapy and SGLT2I use is expected to increase more due to their cardioprotective effects. Proper selection of add-on therapy, based on drug-specific effects and patient factors, is necessary.